NOVONIX Ltd Files Form 6-K
Ticker: NVNXF · Form: 6-K · Filed: May 23, 2024 · CIK: 1859795
Sentiment: neutral
Topics: reporting, foreign-private-issuer, company-info
Related Tickers: NVX
TL;DR
NOVONIX filed a 6-K, confirming 20-F annual reports and Australian incorporation. Nothing major, just housekeeping.
AI Summary
NOVONIX Limited filed a Form 6-K on May 23, 2024, reporting information as of that date. The filing indicates that NOVONIX is a foreign private issuer and will file its annual reports under Form 20-F. The company is incorporated in Australia and its fiscal year ends on December 31.
Why It Matters
This filing provides an update on NOVONIX's reporting status as a foreign private issuer, which is relevant for investors tracking its compliance and financial reporting schedule.
Risk Assessment
Risk Level: low — This is a routine filing confirming reporting status and company information, not indicating any new financial events or risks.
Key Players & Entities
- NOVONIX Limited (company) — Registrant
- 20240523 (date) — Filing Date
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Form
FAQ
What is the filing type and date?
The filing type is a Form 6-K, filed on May 23, 2024.
Is NOVONIX Limited an Australian company?
Yes, the filing indicates NOVONIX Limited is incorporated in Australia.
What form will NOVONIX use for its annual reports?
NOVONIX will file its annual reports under cover of Form 20-F.
What is NOVONIX's fiscal year end?
NOVONIX's fiscal year ends on December 31.
What is the company's principal executive office address?
The principal executive office is located at Level 38, 71 Eagle Street, Brisbane, QLD 4000, Australia.
Filing Stats: 200 words · 1 min read · ~1 pages · Grade level 12.9 · Accepted 2024-05-23 09:19:14
Filing Documents
- nvx-6k-may-24_05-23-pr_c.htm (6-K) — 19KB
- nvx-ex99_1.htm (EX-99.1) — 14KB
- img58969013_0.jpg (GRAPHIC) — 61KB
- 0000950170-24-063771.txt ( ) — 118KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NOVONIX LIMITED By: /s/ Dr. John Christopher Burns Dr. John Christopher Burns Chief Executive Officer Date: May 23, 2024